The development of a preventative HIV vaccine able to elicit broadly neutralizing antibodies (bNAbs) remains a major challenge. Antibodies that recognize the V2 region at the apex of the HIV envelope trimer are among the most common bNAb specificities during chronic infection and many exhibit remarkable breadth and potency.
bNAbs to prevent HIV infection. Passive immunization of bNAbs isolated from infected donors has long been known to protect non-human primates from infection [reviewed in (1) ]. Indeed, a recent study showed that a single injection of bNAbs protected animals against repeated exposure for up to 23 weeks.
2 Furthermore, studies of HIV infected donors have shown that the human immune system has the capacity to make such bNAbs. These findings, along with the failure of traditional vaccine strategies, has led the field to consider next-generation vaccine regimens which are based on detailed studies of the ontogeny of bNAbs during infection, a strategy referred to as the B cell lineage approach. 3 Here, we describe recent virological, immunological, and structural studies supporting and informing this approach, specifically focusing on bNAbs that target the V2 region at the apex of the envelope trimer.
| WHY IS VAN ATTRACTIVE BNAB VACCINE TARGET?
The HIV-1 envelope (Env) glycoprotein complex, which consists of a heterotrimer of three molecules of gp120 and three molecules of gp41, is responsible for mediating viral entry into host cells, and is the sole target of neutralizing antibodies. The first and second variable regions (V1V2) of gp120 are located at the apex of the envelope trimer, and are highly variable in terms of sequence, glycosylation and length, largely due to mutations and insertions in two regions, in the middle of V1 and toward the C-terminal end of V2 ( Figure 1 ). In contrast, semi-conserved regions exist, particularly in the V2 region which is the focus of this review, in strands B and C, including highly conserved glycans at positions 156 and 160 and other fairly conserved residues such as those 166 and 169, which will be described in further detail below. The V1V2 domain is an important contributor to viral entry and neutralization resistance of HIV isolates [reviewed in (4) ].
Studies of transmission pairs suggest that in many cases infection is mediated by viruses with compact V1V2 regions, which subsequently become longer during the course of infection, suggesting a complex interplay between infectivity and the need for neutralization resistance through V1V2 sequence changes, elongation and glycosylation. The role of the V1V2 region in immune evasion is emphasized by the extreme neutralization sensitivity of V1V2-deleted viruses.
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F I G U R E 1 Global alignment and trimeric location of V1V2 within the envelope trimer. The V1V2 region is itself a frequent target of neutralizing antibodies that drive viral escape mutations within this region. [10] [11] [12] [13] [14] [15] In some cases, multiple unrelated B cell lineages target this region, highlighting the immunogenicity of V1V2 during infection. 10 The high variability in this region results in the majority of these autologous neutralizing responses being strain-specific and easy for the virus to evade, providing limited insights for HIV vaccine design. However, within this region, the semi-conserved elements of V2 may also be the target of bNAbs able to recognize diverse circulating viruses, and these are the basis of this review. Thus, while the V1V2 region has long been recognized as a target for antibodies, it was only in 2009 with the isolation of the bNAbs PG9/PG16 that its relevance for vaccine design was truly appreciated.
While almost all infected people develop antibodies to the HIV envelope which have some cross-neutralizing activity, 16 Despite these impediments to bNAb development, much of the surface of the HIV trimer is now known to be vulnerable to bNAbs, with many antibody epitopes including the glycans that provide half of the molecular weight of the HIV envelope, and were initially assumed to function solely as a shield for underlying epitopes. 33, 34 These findings come from the isolation of dozens of broadly neutralizing monoclonal antibodies, 35, 36 largely due to the optimization of relatively new technologies for human antibody isolation including antigen-specific sorting (most recently using trimeric antigens which are particularly important for the quaternary V2-apex bNAbs 37, 38 ), B cell culture with micro-neutralization assays for screening of individual wells, and multiplex RT-PCR for amplifying immunoglobulin genes from single cells
[reviewed in (35, 39, 40) ]. Characterization of these new bNAbs has enabled the field to define several conserved viral epitopes including the V2-apex site that is the focus of this review, as well as the N332 glycan supersite, the membrane proximal external region (MPER), the CD4 binding site (CD4bs), and the gp120-gp41 interface, recently shown to include the fusion peptide. 33, 41 Although many vaccine strategies aim to elicit a polyclonal response that would ideally target multiple conserved epitopes, several approaches are target-specific.
The use of strategies such as minimal epitopes, and have thus resulted in a concerted effort to understand the breadth of antibodies to specific epitopes such as the V2-apex.
Antibodies to the V2-apex may be especially attractive from a vaccine perspective because they are among the most prevalent of broadly neutralizing responses, with mapping studies in several cohorts of infected donors showing that these account for up to a third of bNAb responses. 17, 18, [42] [43] [44] This indicates that the immune system of many individuals is amenable to the development of these specificities. Furthermore, monoclonal antibodies (mAbs) to this epitope have been isolated from several donors (PG9/PG16 from donor IAVI24, the CH01-04 lineage from donor CH0219, the PGT145/PGDM1400
lineage from IAVI84, and the CAP256-VRC26 lineage from CAP256) enabling a comprehensive understanding of their features and neutralization capacity 37, 38, [45] [46] [47] (Table 1 and Figure 2 ). These mAbs all have structural properties in common, such as an unusually long CDR H3 loop that is generally highly anionic. This negative CDR H3 charge is provided both by an abundance of aspartate and glutamate residues, and by sulfation of tyrosines, and facilitates recognition of the positively charged V2 epitope through a shared mode of recognition, described below ( Figure 2 ).
These mAbs often have substantial breadth, neutralizing 70%-85% of viruses, 38, 46, 48 and in some cases remarkable neutralization potency in the nanomolar range. 37, 38, 46, 47 The need to understand future vaccine coverage, and more immediately the potential utility of mAbs in passive immunization, has led to studies using large panels of transmitted/founder viruses (the infecting virus that both active or passive immunization strategies will need to block) and assessed which combinations of bNAbs may provide optimal potential clinical benefit. 48, 49 In one such study, a V2-apex antibody, CAP256-VRC26.25 was included in both the best 2-mAb and 3-mAb combinations, highlighting the potential of this specificity in passive immunization, but also in vaccine-elicited responses. Similarly, a combination of V2-directed PGDM1400 with PGT121 (which targets the N332 supersite) has been shown to achieve extraordinary breadth and potency, neutralizing 98% of that particular panel of viruses at a median IC 50 of 0.007 μg/mL. 38 Although the breadth of some individ- 46 These antibodies led, in 2011, to the first crystal structures of the V1V2 domain, which were achieved using scaffolded constructs, with the V1V2 region engrafted onto a heterologous protein, bound to PG9 55 ( Figure 3A) . Importantly, the recently discovered V1V2-directed bNAbs enabled an "on-column" method, where mAbs were coupled to the column and used to specifically purify properly folded and glycosylated V1V2 scaffolds. Viral strains ZM109 and CAP45, both clade C viruses, were solved at 1.8 Å and 2.2 Å respectively. The structures not only revealed atomic-level details regarding the neutralization mechanism of PG9 but also provided the first glimpse at the two variable domains that cap the trimeric viral envelope. V1V2 was shown to comprise a four stranded beta-sheet with disordered loops between strands A and B and strands C and D, and later structures would reveal an additional strand not seen in the initial scaffolded structures due to dimerization of the V1V2 domains. [56] [57] [58] Although, as described above, V1V2 had long been recognized as a highly variable region, the sequence elements comprising the strands of the domain are more conserved than the outer loop regions ( Figure 1A ). The unusually long CDR H3 engaged strand C of V2 through main-chain interactions forming a parallel β-strand along the edge of the V1V2 sheet. side-chain interactions with this positively charged region buried under the glycan shield. Although the C-strand of V2 is more conserved than the loop regions, the sequence variations that do exist could be better tolerated due to the CDR H3 main-chain interactions with the peptide backbone, which is largely sequence-independent, providing a mechanism for breadth among antibodies targeting this site.
PG9-bound V1V2 revealed how bNAbs could target this region not only by penetrating the glycan shield, but by using the dense array of glycans, typically regarded as a viral defense, as part of their epitope. PG9 neutralization is dependent upon glycans at residues N156 (or N173 in some strains) and N160, with the latter conserved glycan being critical for recognition ( Figure 3A ). The scaffolded proteins in the crystal structures were grown in HEK293S GnTI − cells, which lack N-acetylglucosaminyltransferase I activity, trapping the glycosylation pathway at an early stage. On-column purification further selected scaffolds with glycosylation profiles favorable to PG9 binding, Man5GlcNAc2 (Man5) glycans at N156 and N160. ZM109 falls among a minority of HIV-1 strains that do not have a glycan at N156 but instead contains a glycan at residue N173, which is in close threedimensional proximity to N156 in the structure and serves as a viable substitute. The co-crystal structure of PG16 with a scaffolded V1V2
domain from ZM109, grown in cells treated with the α-mannosidase II inhibitor swainsonine (predicted to induce hybrid-type glycans), highlighted a difference in glycan specificity for this clonal relative of PG9.
These preferences suggest that while glycans at residues N156/N173
and N160 may primarily consist of Man5, 60 they are not completely homogeneous and that antibody lineages differentiate to accommodate various glycoforms, as has been observed also for glycantargeting bNAb specificities to other conserved sites. 61 Comparison of V2-apex targeting bNAbs with non-broadly neutralizing antibodies that target this same region has also yielded useful information. Sieve analysis during the RV144 vaccine trial had detected immune signatures at sites 169 (an important part of bNAb epitopes) and residue 181. This was supported by the isolation of two V2-directed antibodies, called CH58 and CH59, both isolated from RV144
vaccines. These antibodies, despite apparently targeting conserved elements of V2, did not display broadly neutralizing activity. 62 Co-crystal structures of these vaccine-elicited antibodies with a peptide from the V1V2 domain corresponding to the C-strand revealed that these antibodies bound to helical and loop conformations considerably different from those seen in the scaffolded structures ( Figure 3B ). Surface
Plasmon Resonance assays with these antibodies and PG9 confirmed that within a population of monomeric gp120s, the C-strand of V1V2
could adopt multiple conformations, each recognized by a different 
| ELUCIDATING THE TRIMER STRUCTURE PROVIDES NEW TOOLS FOR IMMUNOGEN DESIGN
Broadly neutralizing antibodies that target the V2 region prefer or require a quaternary epitope, [45] [46] [47] which has complicated attempts to elicit such antibodies. The establishment of a soluble prefusion closed trimer 63 enabled these antibodies targeting the trimer interface at the apex of the viral spike to be imaged by negative stain electron microscopy (EM). The first structure, a three-dimensional reconstruction of PG9 in complex with an engineered trimeric envelope called BG505 SOSIP.664, provided a clue as to the quaternary nature of these antibodies. 64 PG9 bound asymmetrically to the cap of the spike with a stoichiometry of a single Fab per trimer ( Figure 3C ). Using the threefold symmetry of the Env and fitting the previously determined scaffolded complex crystal structure with PG9, the authors suggested that PG9
likely would interact with the N156 (or N173) and N160 glycans of the bound protomer, but would likely also bind the N160 glycan of a neighboring protomer ( Figure 3C ). A second EM structure was determined with CAP256-VRC26.09 bound to a BG505 SOSIP.664 trimer and showed a similar result to that of PG9. 47 Analysis of a third antibody, PGDM1400, by EM with 2D class averages revealed that this antibody bound closer to the center of the threefold axis than the previous two, suggesting it may bind in a different manner. trimeric scaffolds in a 96 well format, a scaffold that bound to V2 bNAbs better than monomeric gp120s was identified. A 3.1 Å structure of CH03 (from donor CH0219) on a trimeric V1V2 scaffold, derived from the virus that superinfected donor CAP256 (described in more detail below), showed a very similar mechanism of engagement to that of PG9 57 ( Figure 3D ). Both antibodies bound the C-strand through mainchain strand-strand hydrogen bonds, though PG9 also showed more involved side chain interactions. Both antibodies also bound glycans at N156/N173 and N160. The CH03 structure, however, revealed a glycan interaction not seen in the monomeric structures. Although the orientation of the V1V2 domains in the trimeric scaffold differed from that of the native spike, a glycan from a neighboring protomer, in close proximity to the position of the N160 of a neighboring protomer on the native trimer, bound extensively to CH03 ( Figure 3D ). This quaternary glycan interaction provided the experimental atomic details to support the hypothesis put forward in the PG9-BG505 SOSIP.664 EM study described above. 57 Although an Env-complexed crystal structure remains elusive for the CAP256-VRC26 lineage, data from EM, hydrogen-deuterium exchange, molecular dynamics, and mutagenesis studies all suggest that these antibodies engage the V2 domain through a similar mechanism as PG9/PG16 and CH01-CH04. Similarly for CH01-CH04, two versions of a putative precursor (RUA-1 and RUA-2) were inferred from the complete sequences of the four lineage members (CH01-CH04) isolated from donor CH0219 during chronic infection. 68 They differ by one amino acid in the CDR H3 due to an uncertainty in one non-synonymous position (G/T at position 401 in the CDR H3) of the calculated ancestor. These variants contain fully reverted VH and VL genes, however, the CDR H3s differ from the most closely related mature lineage members by only one or two amino acids for RUA-1 and RUA-2 respectively. These two CH04
| THE ANTIBODY PRECURSORS AND VIRAL TRIGGERS OF V2-APEX LINEAGES
early ancestors neutralized four of 24 tier 2 viruses (i.e. neutralization resistant viruses that represent circulating strains) in one study 17 and RUA-2 neutralized nine of 201 in a second. 57 Next generation sequencing (NGS) data of donor CH0219 was later obtained and indicated that the earliest inferred ancestor, which had a maturation rate of only 0.3%, differed by two amino acids in the CDR H3 from the previously defined RUA-1 or RUA-2, with one change located at the previously uncertain position. 57 Notably, these residues (100e and 100f, Kabat numbering) reside in an area of direct contact with V2, although they form hydrogen bonds through main-chain strand-strand interactions, which may limit the impact of the side chains in this region.
The same approach was taken with the PGT145/PGDM1400 lineage isolated from donor IAVI84, which differs slightly from the other V2 bNAbs as its CDR H3 is extended at less of an angle and the ap- 
| TRIGGERING PRECURSORS OF V2-APEX LINEAGES
The long CDR H3s that characterize V2-apex antibodies range from 24-37 amino acids (Kabat numbering). These are in contrast with typical antibodies, which have a mean length of 14-16 amino acids. bind the vast majority of strains. Indeed, in CAP256 for which the most accurate V2-apex precursor has been determined, the UCA neutralized only the superinfecting transmitted/founder virus, but not the primary transmitted/founder virus or any other virus from a panel of two hundred. 69 Identifying the virus that triggered the lineage was therefore a major interest, especially given that the CAP256-VRC26 lineage was detected only 20 weeks after superinfection. 47, 69 NGS of the viral V2 region revealed variability by week 34 (the first time point at which CAP256-VRC26 transcripts were detected) with descendants of both the primary and superinfecting viruses and recombinants thereof all represented. Three Env variants isolated from week 34 and derived from the superinfecting virus were more sensitive to neutralization by the UCA than the parental CAP256-SU virus, suggesting that they or similar bNAb-initiating envelopes engaged the B cell bearing the UCA, thereby triggering the lineage. 69 Identifying additional such V2-apex bNAb-initiating envelopes has potential utility for immunogen design, but relies on detailed longitudinal sampling, and on these envelopes being generally more reactive with multi-donor V2-apex precursors than other viral envelopes. Previous studies of V2-apex antibodies had sought to identify germline-reactive envelopes for individual lineages as the basis of future immunogens. 68 To empirically determine strains that may inherently offer the most promising combinations of attributes sought in a V2 immunogen, large panel neutralization assays were carried out with mature, intermediate and germline reverted V2 bNAb antibodies from all four known donors. Where longitudinal data were available, UCAs were used, and otherwise V-gene reverted variants with mature CDR H3s served as approximate earliest ancestors. 57, 68, 78 Notably, only a small number of stains were neutralized by these V2 bNAb precursors, with several of the strains such as WITO.33 and ZM233 overlapping between V2-bNAb donors. 57 A parallel independent study also identified some of the same strains using a similar approach. 79 Although each strain individually showed some traits to set them apart from the consensus, no universal particular elements could be detected among the sensitive strains. Interestingly, one of these strains included the CAP256 superinfecting virus (CAP256-SU), a variant of which elicited the CAP256-VRC26 lineage, 69 highlighting the potential utility of longitudinal studies of V2-apex donors in identifying additional useful viral strains for inclusion into immunogens described in more detail below.
| MATURATION OF BREADTH FROM BNAB PRECURSORS
Beyond 
| INCORPORATING ONTOGENY INTO STRUCTURE-BASED IMMUNOGEN DESIGN
Studies of the ontogeny of V2-apex antibodies have led to increased efforts to incorporate structural and virological findings into targeted immunogens. Many clinical trials based on immunization with monomeric gp120 have failed to elicit bNAbs, including those directed to the V2-apex. 82 The structural explanation for this latter finding is that such gp120 monomers do not form the full V2-apex epitope and can adopt multiple conformations of C strand. 62 57, [67] [68] [69] 79 This suggests that, even if the precursors exist in a naive repertoire and a soluble trimer that perfectly recapitulates the native spike is present, V2 bNAb precursors are unlikely to be stimulated unless the appropriate strains are used.
The identification of a few strains that have a higher probability of engaging V2-apex bNAb precursors from multiple donors, described above, 57, 79 opens up possibilities for incorporating these into trimeric immunogens. However, the use of these viral strains to elicit V2-apex bNAbs still includes a number of obstacles. The SOSIP mutations that are used to stabilize soluble trimers such as BG505 SOSIP.664, have been now been integrated into a small number of additional strains to form soluble trimers, 66, [84] [85] [86] and similarly a few strains form stable trimers with a set of mutations termed NFL. 87 However, most strains are unstable or do not display full cleavage, 63, 84 
| CONCLUSIONS
With the availability of a soluble trimer that mimics that native spike, a great many ideas for immunogen design that were technologically 
